A new research paper was published in Oncotarget entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma."
2024
Color blindness and differentiating between choroidal melanoma and choroidal nevus
A few studies have highlighted the differences between healthcare professionals with CVD and those with normal color vision.
TIL Therapy Plus IL-2 as Second-Line Treatment for Advanced Melanoma
Tumor-infiltrating lymphocyte (TIL) therapy in combination with high-dose interleukin-2 (IL-2) should be considered as a second-line treatment of choice for patients with advanced melanoma who have received anti-PD-(L)1 therapy, according to researchers.
BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma
BioNTech has announced positive topline findings from an ongoing phase 2 trial (NCT04526899) evaluating the investigational mRNA cancer immunotherapy BNT111 in combination with cemiplimab (Libtayo) for patients with unresectable stage III or IV melanoma who experienced disease progression following anti-PD-(L)1 therapy.